Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Recruiting · NCT04965766 · Registry updated 2025-12-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-12-23 | NCT04965766 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Daiichi Sankyo | 144 |
| Gustave Roussy, Cancer Campus, Grand Paris | 93 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Antoine Lacassagne | Nice | France | 83 |
| Centre Georges François Leclerc | Dijon | France | 42 |
| Centre Léon Bérard | Lyon | France | 77 |
| CHU de Limoges | Limoges | France | 24 |
| Gustave Roussy | Villejuif | France | 119 |
| Hôpital Tenon | Paris | France | 19 |
| Institut Claudius Regaud | Toulouse | France | 40 |
| Institut Curie | Paris | France | 81 |
| Institut de Cancérologie de l'Ouest | Saint-Herblain | France | 29 |
| Institut Paoli Calmettes | Marseille | France | 38 |
| Institut Régional du Cancer de Montpellier | Montpellier | France | 14 |